Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT05092672 Recruiting - Clinical trials for Essential Hypertension

Physical Activity, Air Pollution, and High Blood Pressure

Start date: November 15, 2021
Phase: N/A
Study type: Interventional

The investigators are investigating the effects of traffic-related air pollution (TRAP) on the cardiovascular and pulmonary response to exercise in patients with hypertension using a real world randomized, crossover study design. Participants will be exposed to 2 conditions: a low TRAP environment and a high TRAP environment. Each exposure will consist of 30 min of moderate-intensity exercise. Cardiovascular and pulmonary health outcomes will be measured before, during, and up to 24 hours following exposures. A minimum washout period of 1 week will be used to minimize carryover effects.

NCT ID: NCT05086549 Completed - Proteinuria Clinical Trials

An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria

FINALE
Start date: September 29, 2021
Phase:
Study type: Observational

This study aims to observe changes in various indicators of renal function, such as proteinuria at different time points: short-term (Week 8), 6 months (Week 26), and a year (Week 52), in patients with DKD and hypertension, who are given antihypertensives containing fimasartan, in an actual clinical environment where a variety of patient characteristics are reflected.

NCT ID: NCT05086523 Recruiting - Clinical trials for Hypertension,Essential

Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study

Start date: September 27, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This washout protocol is structured as a sub-study for patients willing to participate after finishing the double blind randomised phase of the clinical trial, NCT02837445. Devices will be turned off for a week approximately. Patients will have their PHC programmed to automatically turn off 24 hr after a medical and technical visit and remain in regular pacing. Ambulatory recording of the BP will start at the end of the visit, and continue for 24 hr after the turn off time (48 hr recording). Conversely, patients will return at the end of the first week, when a second 48 hr recording will be initiated, this time, the PHC will be programmed to turn on 24 hr later. The recordings therefore will provide data of the ON to OFF transition for the evaluation of the residual effect of PHC after 24 h and after week.

NCT ID: NCT05067998 Recruiting - Chronic Pain Clinical Trials

The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature

Start date: January 21, 2024
Phase:
Study type: Observational [Patient Registry]

Herbal Medicine is known as the medicinal use of herbal substances as a means of treating different conditions in the human body to ensure that the body remains in optimal health and wellness. These substances are known to contain very active ingredients in it and as such is also a very potent means of managing diseases and ailments in the body. Herbal medicine has always been a standby source of getting relief from various conditions over centuries, however, it can be categorically said that the mode of usage of these herbal substances has changed over time. Traditional healers help individuals to make meaning out of the natural herbs seen around that can be useful to one's health. Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Herbs can interact with other pharmaceutical medications and should be taken with care. Always seek a regular medical doctor (GP) about any health concerns and tell them about any herbal medicines you are taking or thinking of taking. Never stop taking prescribed medications in favor of herbs without first discussing it with your GP.

NCT ID: NCT05049096 Terminated - Hypertension Clinical Trials

Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension

PARADISE-HTN
Start date: November 1, 2021
Phase: N/A
Study type: Interventional

This randomized, double blinded, sham-control trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension.

NCT ID: NCT05033535 Recruiting - Clinical trials for Essential Hypertension

s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension

Start date: July 1, 2020
Phase: Phase 2
Study type: Interventional

Efficacy and Safety of s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension:a Randomized,Double-blind,Placebo-controlled,Multicenter Phase II Clinical Trial

NCT ID: NCT04959305 Completed - Hypertension Clinical Trials

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

HM_APOLLO
Start date: April 22, 2021
Phase: Phase 2
Study type: Interventional

A multicenter, randomized, double-blind, parallel, phase 2 study to explore the dose of HCP1803 in patients with essential hypertension

NCT ID: NCT04915313 Completed - Prehypertension Clinical Trials

The Antihypertensive Effect of Remote Ischemic Conditioning (RIC-HTN).

Start date: June 15, 2021
Phase: N/A
Study type: Interventional

This study intends to further reveal the antihypertensive effect of LRIC and explore its potential mechanisms.

NCT ID: NCT04863508 Recruiting - Clinical trials for Hypertension,Essential

Wearable Blood Pressure Devices to Identify Masked Uncontrolled Hypertension.

Start date: November 26, 2020
Phase:
Study type: Observational

Uncontrolled out-of-office blood pressure (BP), measured by either home BP monitoring (HBPM) or ambulatory BP monitoring, has been shown to predict higher cardiovascular risk. However, HBPM could not identify daytime BP surge, which leads to underestimation of future risk among treated hypertensive individuals. HeartGuide provides validated out-of-office BP measurements, along with activity/sleep recordings. The present study is designed to examine whether BP monitoring with the HeartGuide could identify masked uncontrolled hypertension in controlled hypertensive patients based on office BP. We will enroll hypertensive patients with controlled office BP according to their cardiovascular risk profile. We will also examine prevalence of post-prandial BP changes and BP variability using HeartGuide.

NCT ID: NCT04830449 Completed - Hypertension Clinical Trials

Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients

Start date: October 29, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate of efficacy and safety of HCP1904-2 and RLD2001-2 alone in patients with essential hypertension inadequately controlled on RLD2001-2 monotherapy.